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ReproducibilityBackground and purpose: To investigate the feasibility and to determine the repeatability of recurrent
[18F]HX4 PET scans in patients with oesophageal (EC) and pancreatic (PC) cancer.
Materials and methods: 32 patients were scanned in total; seven patients (4 EC/3 PC) were scanned 2, 3
and 4 h post injection (PI) of [18F]HX4 and 25 patients (15 EC/10 PC) were scanned twice 3.5 h PI, on two
separate days (median 4, range 1–9 days). Maximum tumour to background ratio (TBRmax) and the
tumour hypoxic volume (HV) (TBR > 1.0) were calculated. Repeatability was assessed using Bland–
Altman analysis. Agreement in localization was calculated as the distance between the centres of mass
in the HVs.
Results: For EC, the TBRmax in the tumour (mean ± SD) was 1.87 ± 0.46 with a coefﬁcient of repeatability
(CoR) of 0.53 (28% of mean). The HV ranged from 3.4 to 98.8 ml with a CoR of 5.1 ml. For PC, the TBRmax
was 1.72 ± 0.23 with a CoR of 0.27 (16% of mean). The HV ranged from 4.6 to 104.0 ml with a CoR of
7.8 ml. The distance between the centres of mass in the HV was 2.2 ± 1.3 mm for EC and 2.1 ± 1.5 mm
for PC.
Conclusions: PET scanning with [18F]HX4 was feasible in both EC and PC patients. Amount and location of
elevated [18F]HX4 uptake showed good repeatability, suggesting [18F]HX4 PET could be a promising tool
for radiation therapy planning and treatment response monitoring in EC and PC patients.
 2015 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 116 (2015) 94–99Oesophageal and pancreatic carcinomas are difﬁcult to treat
and have a very poor prognosis. (Chemo)radiotherapy plays a key
role in both the curative and palliative treatment of these cancers
[1,2]. Although these treatment regimens improve patient out-
come, treatment response ﬂuctuates greatly between patients
and overall survival remains poor. For oesophageal cancer,
complete response to neoadjuvant chemoradiation varies between
15% and 40% [3]. Studies investigating the efﬁcacy of
(radio)chemotherapy in patients with pancreatic ductal adenocar-
cinoma generally show an overall limited gain in median survival
[4–6]. Oesophageal carcinomas have been associated with reduced
oxygenation and resulting hypoxia related gene-expression [7].
The pancreatic tumour microenvironment is characterized by
hypoxia, resulting from an abundance of stromal tissue andreduced vascularization [8–10]. Several studies have shown the
relation of tumour hypoxia with adverse outcome in both oesopha-
geal [11] and pancreatic cancer [12]. Hypoxia driven cell preserv-
ing pathways are associated with a more aggressive and
metastatic tumour phenotype as well as resistance to chemother-
apy and radiation [13–16]. The ionizing damage of radiation is
increased by the formation of oxygen radicals. In hypoxic condi-
tions the shortage of oxygen leads to a decreased effectiveness,
and it is suggested that higher doses of radiation are needed to
induce the same therapeutic effect, also known as the Oxygen
Enhancement Ratio (OER) [17,18].
Reliable visualization of the distribution of hypoxic areas within
the tumour may enable tailor made radiation therapy. Several
techniques may deal with this: ﬁrst, dose painting techniques
may be used to increase the radiation dose to the hypoxic areas.
Modern radiotherapy planning techniques as intensity modulated
radiotherapy (IMRT), conformal arc techniques, tomotherapy and
proton therapy can potentially enable selective delivery of a higher
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[19,20]. Second, radiation therapy or chemotherapy can be com-
bined with various other modalities to enhance their effect on
hypoxic tumours in case clinically relevant hypoxia is present.
Options are the addition of carbogen breathing, radio-sensitizing
agents as nimorazole or regional hyperthermia to enhance the
effect of radiation or chemotherapy [21–23]. Furthermore, hypoxia
activated pro-drugs as TH-302 can be used to speciﬁcally target
hypoxic tumours [24,25]. Hypoxia PET imaging can be used to
identify tumour hypoxia and could serve as a potential predictive
marker to select those patients that would beneﬁt from these
hypoxia targeting treatment regimens [26–29].
2-nitroimidazole PET tracers have been developed to
spatially identify and quantify hypoxic tumour areas. Due to the
oxidation step involved in cell clearance, cell accumulation of
2-nitroamidazole derivatives is directly dependent on the intracel-
lular pO2 [30]. In recent years several 2-nitroimidazole derivatives
have been developed and their ability to visualize in vivo tumour
hypoxia has been studied in several tumour types [31,32].
[18F]-3-Fluoro-2-(4-((2-nitro-1H-imidazol-1-yl)methyl)-1H-1,
2,3-triazol-1-yl)propan-1-ol ([18F]HX4, ﬂortanidazole, Threshold
Pharmaceuticals) is a relatively new 2-nitroimidazole derivative,
which was developed to visualize hypoxic tumour areas.
[18F]HX4 may have a higher sensitivity, speciﬁcity and faster
background clearance when compared in vivo to the most com-
monly used nitroimidazole hypoxia marker [18F]FMISO. Earlier
studies showed promising results using [18F]HX4 as a hypoxia
marker [33–37]. Similar tumour distribution was found for
[18F]HX4 and the most commonly used nitroimidazole hypoxia
marker [18F]FMISO in head and neck cancer [38]. Furthermore,
both rat and mouse tumour models showed good correspondence
of [18F]HX4 tracer distribution with immunohistochemical stain-
ings for hypoxia [33,39].
So far [18F]HX4 has not been used to image hypoxia in oesopha-
geal and pancreatic cancer. For future use in response evaluation
and therapy guidance, a priori knowledge of variations in the mea-
surements is important to distinguish treatment related effects
from method related variations. Hence, knowledge of the repeata-
bility of [18F]HX4 PET scans is essential. The aim of this study was
to investigate the feasibility to perform [18F]HX4 PET in patients
with oesophageal and pancreatic cancer and to determine the
repeatability of repeated measures of [18F]HX4 PET in these cancer
types.Materials and methods
Patients
Thirty-ﬁve patients with pathology proven oesophageal or pan-
creatic cancer were prospectively recruited. The study was
approved by the medical ethics committee of the Academic
Medical Center (University of Amsterdam) and informed consent
was obtained from all individual participants included in the study.
All scans were acquired before the start of initial cancer treatment.[18F]HX4 PET/CT
Imaging was performed on a GEMINI TF 16 PET/CT scanner
(Philips Healthcare, Best, The Netherlands). Patients were scanned
in supine position with their arms above their heads. A single bed
position with an axial ﬁeld of view of 18 cm was acquired of the
primary tumour site for a total acquisition time of 15 min.
PET images were corrected for scatter and attenuation based on
a low dose CT (LDCT) scan and reconstructed using a 3D
ordered-subset iterative time-of-ﬂight reconstruction algorithm
with 3 iterations and 33 subsets. Resulting pixel spacing was4  4 mm and 4 mm slice thickness with a spatial resolution of
approximately 5 mm full width at half maximum (FWHM).
[18F]HX4 was synthesized at the VU University Medical Center
as described previously [33,35]. The injected dose was
434 ± 73 MBq based on an earlier performed phase 1 trial by van
Loon et al. [35].
For protocol optimization, seven patients (4 oesophageal/3 pan-
creatic cancer) were scanned on one day, 2, 3 and 4 hours (h) post
injection (PI) of [18F]HX4. To investigate repeatability, 25 patients
(15 oesophageal/10 pancreatic cancer) were scanned twice, on
two separate days. Based on the results of the optimization study,
showing only a minor increase in TBRmax between 3 and 4 h PI,
and to be able to scan study patients directly following the clinical
programme, patients in this group were scanned 3.5 h PI. Patients
did not receive any further preparation instruction before the
scans.Image analysis
Repeated scans of the same patient were co-registered to match
the ﬁrst scan by maximizing the mutual information between the
LDCT images, followed by an afﬁne and b-spline registration in
Elastix [40]. The corresponding PET images were then transformed
according to the found parameters. After registration, the following
volumes of interest (VOI) were drawn based on the LDCT: the
tumour area in the oesophagus or pancreas and the aorta.
Separately acquired diagnostic contrast enhanced CT images were
used as reference for better tumour localization. The [18F]HX4 PET
scans were projected on the LDCT during VOI delineation, to make
sure no activity spill from the liver or bile ducts was projected into
the tumour VOIs.Quantitative measures
Uptake concentrations were converted to standardized uptake
values (SUV), correcting for injected dose and patient weight.
Maximum tumour to background ratio (TBRmax) was calculated
as the voxel with the maximum SUV value in the tumour VOI
(SUVmax), divided by the average SUV of the voxels in the aorta
VOI (SUVmean).
We deﬁned the hypoxic volume (HV) as all voxels within the
tumour VOI with TBR >1.0. This way all voxels with elevated
[18F]HX4 uptake compared to the blood pool are identiﬁed,
whereas these voxels would be the most relevant for clinical prac-
tice. In addition, the HV was calculated for thresholds TBR >1.1 to
TBR >1.4.
To evaluate correspondence in distribution of uptake intensity
between the repeated scans, the voxels within this HV were used
to calculate the centre of mass. The centre of mass was calculated
by multiplying the activity of a voxel by its location in space for the
x, y and z coordinate, divided by the total activity in the HV. In this
way both the geometry of the HV and the distribution of [18F]HX4
uptake are incorporated in one measure (see Fig. 1). The Euclidean
distance between the centres of mass in the HV of the repeated
scans was used to measure the repeatability in uptake distribution
between the scans.Statistical analysis
For statistical analysis the Prism 5.01 (GraphPad Software Inc.,
La Jolla, CA, USA) software package was used.
We used Wilcoxon signed rank test to calculate differences
between, SUVmax, SUVmean, TBRmax on the 2 h, 3 h and 4 h Pi
scans. Differences between SUVmax, SUVmean, TBRmax and HV
between the scans on day 1 and 2 were also calculated using this
Fig. 1. 2D example of the Centre of Mass (green dot) of the area with TBR > 1.0 (green line) within the tumour ROI on day 1 and day 2 after registration. The black dot
indicates the location of maximum intensity. On the left the LDCT on day 1 is shown with reference area (red box).
Table 1
Patient characteristics.
Patient Age Gender Pathology Stage
Oesophagus
Optimization EC1 54 M SCC T3N3M0
EC2 65 M AC T3N2M0
EC3 76 M AC T3N1M0
EC4 67 M AC T3N1M0
Repeatability EC5 61 M AC T3N0M1
EC6 51 M AC T3N0M0
EC7 53 M AC T3N1M0
EC8 53 M AC T3N2M0
EC9 55 M AC T3N1M0
EC10 64 M SCC T3N2M0
EC11 71 M SCC T2N2M0
EC12 48 M AC T2N0M0
EC13 60 M AC T3N2M0
EC14 59 F AC T3N3M0
EC15 55 M AC T3N2M0
96 Repeatability of [18F]HX4 PETmethod. p < 0.05 was considered statistically signiﬁcant. Results
are given in mean ± standard deviation (SD).
To determine the repeatability of tumour SUVmax, TBRmax and
HV, the methods described by Bland and Altman were used [41]. In
the Bland–Altman plot the difference between the measurements
on day 1 and 2 is plotted versus the average on both days. The coef-
ﬁcient of repeatability is calculated as 1.96 times the standard
deviation of the difference between the paired measures. The
lower and upper limit of agreement plotted in the Bland–Altman
plot indicate the 95% conﬁdence interval of normal variation in
the measurements and are deﬁned as the mean difference
between the repeated measures minus or plus the coefﬁcient of
repeatability. Values outside the limits of agreement can be consid-
ered real biological changes, for instance indicating response to
treatment. The repeatability index is deﬁned as the coefﬁcient of
repeatability divided by the average of all repeated measurements
times 100%.EC16 68 M AC T3N0M0
EC17 61 M AC T3N1M0
EC18 55 F SCC T3N3M0
EC19 55 M AC T3N2M0
Pancreas
Optimization PC1 64 M AC T4N0M0
PC2 53 M AC T4N0M0
PC3 55 F AC T4N0M0
Repeatability PC4 74 M AC T4N0M1
PC5 53 M AC T4N1M1
PC6 47 F AC T4N0M0
PC7 60 M AC T4N1M1
PC8 72 M AC T3N0M1
PC9 59 M AC T3N1M1
PC10 60 F AC T3N0M1
PC11 74 M AC T4N0M1
PC12 49 M AC T4N1M1
PC13 70 M AC T3N0M0
ECx: oesophageal cancer. PCx: pancreatic cancer. SCC: squamous cell carcinoma, AC:
adenocarcinoma.Results
Data of thirty-two patients (5 females, 27 males) were available
for further analysis (Table 1). Two patients did not complete the
second repeatability scan, because the produced [18F] HX4 did
not pass quality requirements. One patient did not show up for
the second scan.
Mean age of the patient group was 60 ± 8 years (range 47–
76 years). The optimization group consisted of 4 oesophageal can-
cer patients (1 squamous-cell carcinoma and 3 adenocarcinoma)
and 3 patients with pancreatic ductal adenocarcinoma. The
repeatability group consisted of 15 oesophageal cancer patients
(3 squamous-cell carcinoma and 12 adenocarcinoma), and 10
patients with pancreatic ductal adenocarcinoma. All diagnoses
were conﬁrmed by pathological examination.
Due to technical issues, one 3 h PI scan failed. The remaining
scans all showed good image quality. Mean SUVmax in the tumour
VOI decreased slightly 2 h to 3 h (1.58 ± 0.38 to 1.35 ± 0.17,
p = 0.44) and 3 h to 4 h PI (1.35 ± 0.17 to 1.27 ± 0.22, p = 0.063),
resulting in a signiﬁcant decrease from 2 h to 4 h PI (1.58 ± 0.38
to 1.27 ± 0.22, p = 0.016). SUVmean in the aorta VOI also decreased
between 2 h and 4 h PI (1.12 ± 0.25 to 0.81 ± 0.21, p = 0.016).
Overall the mean tumour TBRmax slightly increased in time from
1.50 ± 0.29 at 2 h PI, to 1.64 ± 0.39 at 3 h PI (p = 0.16), up to
1.67 ± 0.56 at 4 h PI (p = 0.30), although these differences were
not statistically signiﬁcant.
Median time between the two repeatability scans was 4 days
(range 1–9 days). All repeated scans showed comparable image
quality. Although 5 patients did receive a somewhat lower dose
of [18F]HX4 in one of their repeated scans, this did not result in dif-
ferences in image quality and analysis was performed as in all
other repeated scans.
Typical examples of repeated [18F]HX4 scans in both a patient
with oesophageal cancer and a patient with pancreatic cancer are
shown in Fig. 2A.Overall TBRmax for oesophageal cancer (1.87 ± 0.46) was
slightly higher compared to pancreatic cancer (1.72 ± 0.23) for
all scans. The HV (TBR > 1.0) ranged from 3.4 to 98.8 ml for oeso-
phageal cancer and 4.6 to 104.0 ml for pancreatic cancer. For
both oesophageal and pancreatic cancer, no signiﬁcant differ-
ences were observed in aorta SUVmean, tumour SUVmax,
TBRmax and HV between the scans on day 1 and day 2
(Table 2). The coefﬁcient of repeatability for the TBRmax was
0.53 in oesophageal cancer and 0.27 in pancreatic cancer.
Tumour TBRmax showed a slightly better repeatability index
compared to SUVmax for both cancer types (Table 3). The
Bland–Altman plots for TBRmax and HV for both cancer types
are shown in Fig. 2B.
We did not observe an effect from the timing between the two
repeated scans on the variation between the measurements. When
dichotomized at the median interval of 4 days, separating the scans
Fig. 2. (A) Typical [18F]HX4 TBR images on day 1 and day 2 after registration, showing a patient with a squamous cell carcinoma in the mid oesophagus (top) and a patient
with an adenocarcinoma in the tail of the pancreas (bottom), indicated by the crosshair. Physiological uptake of [18F]HX4 is visible in the muscles, liver, kidneys and large
intestine. (B) Bland–Altman plots showing the variation in TBR and HV (TBR > 1.0) between the repeated scans for both oesophageal and pancreatic cancer. The blue line
indicates the mean difference and the red dashed lines indicate the limits of agreement.
Table 2
Parameters of the 2 repeated [18F]HX4 PET studies for oesophageal and pancreatic cancer and the distance between the centres of mass of the tumour VOI.
Patient Dose (MBq) Tumour SUVmax Aorta SUVmean TBRmax HV (ml) D
(mm)
1 2 1 2 1 2 1 2 1 2
EC5 419 430 1.04 1.13 0.74 0.77 1.41 1.47 30.2 33.1 1.8
EC6 440 441 1.04 0.93 0.71 0.65 1.47 1.43 17.9 15.0 1.4
EC7 199 466 1.01 1.09 0.66 0.65 1.52 1.67 14.9 19.7 2.3
EC8 264 451 1.01 1.03 0.52 0.64 1.93 1.60 29.1 29.6 1.2
EC9 236 452 1.60 1.18 0.59 0.56 2.73 2.12 40.6 37.9 5.1
EC10 374 457 1.59 1.81 0.66 0.72 2.42 2.51 40.8 45.9 1.0
EC11 464 486 1.01 0.76 0.82 0.58 1.24 1.31 3.4 4.7 2.5
EC12 469 483 1.11 1.11 0.66 0.70 1.67 1.60 14.0 15.2 1.0
EC13 437 480 1.31 2.18 0.75 1.06 1.76 2.05 15.6 18.6 0.9
EC14 467 480 1.59 0.84 0.81 0.44 1.97 1.91 31.7 35.9 2.0
EC15 442 461 1.66 1.84 0.63 0.58 2.63 3.16 87.6 86.7 3.1
EC16 464 451 1.66 1.95 0.92 0.93 1.80 2.11 43.7 43.6 3.7
EC17 466 214 1.19 1.37 0.71 0.75 1.68 1.83 26.3 26.3 2.2
EC18 476 434 1.09 1.10 0.51 0.55 2.14 2.02 98.8 97.4 0.7
EC19 462 426 0.81 0.84 0.59 0.55 1.37 1.54 22.2 25.1 4.2
Mean 405 441 1.25 1.28 0.68 0.67 1.85 1.89 34.5 35.6 2.2
SD 94 66 0.29 0.37 0.11 0.11 0.46 0.48 26.5 25.6 1.3
p NS (p = 0.16) NS (p = 0.39) NS (p = 0.80) NS (p = 0.36) NS (p = 0.09)
PC4 470 442 1.53 1.70 0.77 0.79 1.98 2.17 77.2 80.7 1.0
PC5 453 484 1.34 1.26 0.80 0.79 1.67 1.60 41.4 47.7 1.1
PC6 388 475 1.41 1.29 0.90 0.89 1.57 1.45 20.2 21.6 1.7
PC7 474 448 1.59 1.58 0.88 0.84 1.80 1.89 95.6 104.0 1.0
PC8 489 486 1.52 1.82 0.89 1.02 1.70 1.79 5.9 5.2 2.6
PC9 475 487 1.41 1.33 0.74 0.63 1.91 2.12 13.5 14.2 4.5
PC10 456 456 1.42 1.44 0.82 0.90 1.73 1.59 18.8 23.7 4.8
PC11 456 445 1.27 1.30 0.89 0.78 1.43 1.67 17.2 13.6 1.5
PC12 458 440 0.96 0.58 0.54 0.34 1.78 1.72 28.4 25.9 0.6
PC13 441 461 1.13 0.76 0.83 0.55 1.36 1.39 6.2 4.6 2.7
Mean 456 462 1.36 1.31 0.81 0.75 1.69 1.74 32.4 34.1 2.1
SD 28 19 0.19 0.39 0.11 0.20 0.20 0.26 30.6 33.5 1.5
p NS (p = 0.82) NS (p = 0.49) NS (p = 0.19) NS (p = 0.38) NS (p = 0.38)
ECx: oesophageal cancer. PCx: pancreatic cancer. SUV: standardized uptake value. TBR: tumour to background ratio. D: distance between the centres of mass within the
tumour hypoxic volumes (HV). SD: standard deviation. NS: non-signiﬁcant (p < 0.05) with Wilcoxon signed rank test.
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difference in variation between the groups.
The distance between the centres of mass in the HV on day 1
and 2 after registration was 2.2 ± 1.3 mm (range 0.7–5.1 mm) for
oesophageal cancer and 2.1 ± 1.5 mm (range 0.6–4.8 mm) for pan-
creatic cancer, both falling within the FWHM of the scanner
(approximately 5 mm).Discussion
Hypoxia of tumours is of prognostic importance. In addition, it
hampers the efﬁcacy of treatments such as radiotherapy and
chemotherapy. This treatment resistance may be overcome by
adding hypoxia modifying drugs or hyperthermia or by irradiating
the hypoxic areas with a higher dose [19–21,23,25]. Hence,
Table 3
Repeatability parameters of the 2 repeated [18F]HX4 PET studies for oesophageal (EC) and pancreatic (PC) cancer.
Mean ± SD Range Meandiff ± SDdiff CoR (RI) CI
EC SUVmax 1.26 ± 0.33 0.76–1.95 0.03 ± 0.20 0.38 (30%) 0.41–0.36
TBRmax 1.87 ± 0.46 1.24–3.16 0.04 ± 0.27 0.53 (28%) 0.57–0.49
HV (ml) 35.0 ± 25.6 3.4–98.8 1.2 ± 2.6 5.1 (15%) 6.3–3.9
PC SUVmax 1.33 ± 0.30 0.58–1.82 0.05 ± 0.21 0.41 (31%) 0.36–0.47
TBRmax 1.72 ± 0.23 1.36–2.17 0.04 ± 0.14 0.27 (16%) 0.31–0.23
HV (ml) 33.3 ± 31.2 4.6–104.0 1.7 ± 4.0 7.8 (23%) 9.4–6.1
SUVmax: Maximum Standardized Uptake Value. TBRmax: Maximum Tumour to Background Ratio. HV: Hypoxic Volume. Meandiff and SDdiff: Mean and standard deviation of the
difference between scan 1 and scan2. CoR: Coefﬁcient of Repeatability. RI: Repeatability Index. CI: 95% Conﬁdence Interval of difference.
98 Repeatability of [18F]HX4 PETimaging of tumour hypoxia has potential value for therapy guid-
ance. Furthermore, imaging of hypoxia may be used as a prognostic
parameter and for response evaluation after radiochemotherapeu-
tic treatment. The hypoxia marker ﬂortanidazole [18F]HX4 is a
potential candidate for imaging of hypoxia. However, the repeata-
bility, and thus the quantifyability of this compound is mostly
unknown. The aim of this study was to investigate the feasibility
and determine the repeatability of [18F]HX4 PET scans in oesopha-
geal and pancreatic cancer.
We found that image contrast and TBR was highest 4 h after
injection of [18F]HX4. These ﬁndings are in accordance with earlier
studies investigating image contrast at different time points PI of
[18F]HX4 [33,36]. Although scanning at a later time point did not
further increase TBR in a preclinical study [33], no patient studies
investigating later time points than 4 h PI have been performed
yet. The clinical implications of a longer accumulation period are
not attractive, since it would require either a higher injected dose
or longer acquisition time and a longer waiting period for the
patient.
The Bland-Altman analysis of the TBRmax in our study showed
that a normal variation of 28% in TBRmax can be expected for oeso-
phageal cancer and 16% for pancreatic cancer. Thus, for monitoring
of treatment response, effects must induce a greater change than
this to be detectable. Studies investigating dynamics of hypoxic
areas before and during (chemo)radiation suggest that hypoxia
indeed changes in the course of treatment and moreover, residual
hypoxia after the ﬁrst courses of treatment has a higher prognostic
value than baseline hypoxia [26,42–46]. The normal variation in
[18F]HX4 uptake we found in this study was lower than the
changes found during treatment, suggesting it to be able to assess
these changes and thus as a potential tool for early response
evaluation.
The number of studies investigating hypoxia PET in oesophageal
and pancreatic cancer is limited. A study with 10 oesophageal
squamous cell carcinomas showed great variations in tumour
uptake and heterogeneity when [18F]FETNIM was used as a
hypoxia tracer [47]. In contrast, our results showed more clustered
areas of hypoxia, with good repeatability. Compared to an earlier
in vivo study where [18F]FMISO hypoxia imaging was performed
in pancreatic cancer, we observed higher image contrast and were
better able to visually identify areas with increased tracer uptake
[48]. This could well be explained by the longer time between
injection and scanning (2 h vs. 3.5 h) and the faster background
clearance of [18F]HX4 compared to [18F]FMISO [38].
In a study investigating the reproducibility of [18F]FMISO PET in
11 patients with head and neck cancer similar variations in TBR
and HV were found as for [18F]HX4 in our study [49]. The repeata-
bility we found for [18F]HX4 SUVmax in the current study is in the
same range as the repeatability found for [18F]FDG PET, that has a
normal variation of 25–30% [50]. However, it should be noted in
the context of radiotherapy planning, that SUV based delineation
of a volume is more challenging for low contrast tracers, like
hypoxia tracers, compared to high contrast tracers as [18F]FDG.Our results show that TBRmax was more stable in repeated
scans than SUVmax. Furthermore, TBR images make it possible to
apply a general threshold to visually identify hypoxic areas. For
future use of [18F]HX4 in radiation planning, visualization of TBR,
rather than the more regularly used SUV images, could help in a
more robust delineation of hypoxic tumour areas. Future in vivo
studies correlating histology derived parameters of hypoxia to
[18F]HX4 uptake could provide the information necessary for quan-
titative interpretation of hypoxic areas (clinicaltrials.gov:
NCT01989000). However, correlation with dedicated anatomical
imaging is still needed for reliable tumour delineation.
The current approach in our study revealed several shortcom-
ings, worthy of future investigation. First, we did not correlate
[18F]HX4 uptake regions to local [18F]FDG uptake in this study,
since only limited [18F]FDG scans were available in our study
population. However, investigating this correlation might well be
valuable for further tumour characterization, since [18F]FDG distri-
bution is suggested to represent additional biological information
compared to hypoxia tracers [51,52].
Second, we did not investigate the voxel-by-voxel correlation
of [18F]HX4 uptake between the repeated scans. Due to lack of
closely related bony features and lack of soft tissue contrast on
the LDCT, image registration in the areas we investigated is more
challenging compared to for instance the head and neck area.
Although the registration of the LDCT scans showed good results,
we therefore did not assume a one-on-one voxel correlation after
registration. Furthermore, for radiation planning, regions of inter-
est rather than separate voxels are used. Therefore, for radiation
purposes clustered voxels showing elevated uptake are more
important than per-voxel [18F]HX4 uptake. We therefore used
distance between the centres of mass between elevated
[18F]HX4 uptake as a more appropriate measure to compare
uptake localization.
Last, both the oesophagus and pancreas are prone to respiratory
motion. Organ motion during image acquisition will result in
smear of the high intensity areas into wider areas of lower inten-
sity, affecting SUV/TBRmax and consequently HV calculations.
Correction for respiratory motion, e.g. by 4D acquisition, could be
worthwhile for better identiﬁcation of small hypoxic areas and a
more accurate delineation of hypoxic regions.
In conclusion, we demonstrated the feasibility to perform
[18F]HX4 PET imaging in both oesophageal and pancreatic cancer.
Our results show that [18F]HX4 TBRmax and HV can be measured
with good repeatability. This good agreement in location and size
of regions with elevated [18F]HX4 uptake between repeated mea-
sures suggest [18F]HX4 PET could be a promising tool for response
prediction as well as a more targeted approach in radiation
planning.Conﬂict of interest
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